{"id":14,"date":"2026-08-17T12:53:22","date_gmt":"2026-08-17T12:53:22","guid":{"rendered":"https:\/\/peptide-doc.com\/learn\/retatrutide-vs-tirzepatide-vs-semaglutide\/"},"modified":"2026-09-02T19:41:50","modified_gmt":"2026-09-02T19:41:50","slug":"retatrutide-vs-tirzepatide-vs-semaglutide","status":"publish","type":"learn_article","link":"https:\/\/peptide-doc.com\/de\/learn\/retatrutide-vs-tirzepatide-vs-semaglutide\/","title":{"rendered":"Retatrutide vs. Tirzepatide vs. Semaglutide"},"content":{"rendered":"
\nMETA-TITLE:<\/strong> [TODO: Retatrutide vs Tirzepatide vs Semaglutide \u2014 Comparison | Brand]
\nMETA-DESC:<\/strong> [TODO: Side-by-side comparison of three GLP-1 pathway peptides \u2014 receptor targets, efficacy data, safety, research protocols.]\n<\/div>\n

[TODO]<\/span> Hook \u2014 three generations of incretin-based peptides (mono \u2192 dual \u2192 triple agonist), why researchers compare them, what this guide covers<\/p>\n

[IMAGE: Side-by-side comparison infographic \u2014 3 columns: Semaglutide \/ Tirzepatide \/ Retatrutide with key stats]<\/div>\n

Quick Comparison<\/h2>\n
    \n
  • [TODO]<\/span> Table: Receptor targets \u2014 GLP-1 only vs GLP-1+GIP vs GLP-1+GIP+GCGR<\/li>\n
  • [TODO]<\/span> Table: Max weight reduction in trials \u2014 ~15% vs ~22% vs ~24%<\/li>\n
  • [TODO]<\/span> Table: Half-life \u2014 ~7d vs ~5d vs ~6d<\/li>\n
  • [TODO]<\/span> Table: Developer \u2014 Novo Nordisk vs Eli Lilly vs Eli Lilly<\/li>\n
  • [TODO]<\/span> Table: Approval status \u2014 FDA approved vs FDA approved vs Phase 3<\/li>\n<\/ul>\n

    Semaglutide Profile<\/h2>\n
      \n
    • [TODO]<\/span> GLP-1 mono-agonist, longest track record, most safety data<\/li>\n
    • [TODO]<\/span> STEP\/SELECT\/FLOW trials \u2014 weight, CV, renal outcomes<\/li>\n
    • [TODO]<\/span> Established titration protocol, well-characterized side effect profile<\/li>\n<\/ul>\n

      Tirzepatide Profile<\/h2>\n
        \n
      • [TODO]<\/span> First dual GLP-1\/GIP agonist, superior to semaglutide in SURPASS-2<\/li>\n
      • [TODO]<\/span> Unique GIP component \u2014 may reduce nausea vs pure GLP-1 agonists<\/li>\n
      • [TODO]<\/span> Broader metabolic effects \u2014 insulin sensitivity, lipid metabolism<\/li>\n<\/ul>\n

        Retatrutide Profile<\/h2>\n
          \n
        • [TODO]<\/span> Triple agonist \u2014 adds glucagon receptor for energy expenditure<\/li>\n
        • [TODO]<\/span> Highest weight reduction in Phase 2 data, liver fat reduction notable<\/li>\n
        • [TODO]<\/span> Least clinical data \u2014 Phase 2 only, Phase 3 ongoing<\/li>\n<\/ul>\n

          Head-to-Head Research Findings<\/h2>\n
          [IMAGE: Bar chart comparing weight reduction percentages across landmark trials]<\/div>\n
            \n
          • [TODO]<\/span> Efficacy progression \u2014 each generation shows numerically greater weight reduction<\/li>\n
          • [TODO]<\/span> Cross-trial comparison caveats \u2014 different populations, durations, titration schedules<\/li>\n
          • [TODO]<\/span> GI tolerability \u2014 triple agonist does not appear significantly worse<\/li>\n
          • [TODO]<\/span> Metabolic markers \u2014 liver fat, lipids, HbA1c across all three<\/li>\n<\/ul>\n

            Choosing Between Them (Research Context)<\/h2>\n
              \n
            • [TODO]<\/span> Most established data \u2192 Semaglutide<\/li>\n
            • [TODO]<\/span> Best efficacy with approval \u2192 Tirzepatide<\/li>\n
            • [TODO]<\/span> Highest preliminary efficacy \u2192 Retatrutide<\/li>\n
            • [TODO]<\/span> Research availability, cost, protocol design considerations<\/li>\n<\/ul>\n

              Frequently Asked Questions<\/h2>\n
              [FAQ: Can these peptides be combined in research protocols?]<\/div>\n
              [FAQ: Which has the best GI tolerability profile?]<\/div>\n
              [FAQ: Is there direct head-to-head clinical trial data?]<\/div>\n
              [FAQ: How do reconstitution and storage differ between the three?]<\/div>\n

              Related Products<\/h2>\n

              [TODO]<\/span> Link to Semaglutide, Tirzepatide, Retatrutide product pages<\/p>\n","protected":false},"excerpt":{"rendered":"

              [META-DESC TODO: Head-to-head comparison of Retatrutide, Tirzepatide, and Semaglutide \u2014 mechanisms, efficacy, side effects.]<\/p>\n","protected":false},"featured_media":0,"template":"","learn_category":[2],"class_list":["post-14","learn_article","type-learn_article","status-publish","hentry","learn_category-weight-management"],"_links":{"self":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/14","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article"}],"about":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/types\/learn_article"}],"version-history":[{"count":1,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/14\/revisions"}],"predecessor-version":[{"id":37,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/14\/revisions\/37"}],"wp:attachment":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/media?parent=14"}],"wp:term":[{"taxonomy":"learn_category","embeddable":true,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_category?post=14"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}